Validation of the {Delta}SUVmax for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial

Conclusion: We recommend the use of the SUVmax alone rather than the Menton 2011 criteria for assessing the interim metabolic response in patients with diffuse large B-cell lymphoma, except when the baseline SUVmax is less than 10.0.

Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Itti, E., Blanc-Durand, P., Berriolo-Riedinger, A., Kanoun, S., Kraeber-Bodere, F., Meignan, M., Gat, E., Gouill, S. L., Casasnovas, R.-O., Bodet-Milin, C. Tags: Clinical Investigations Source Type: research